Month: February 2022

Despite global COVID shutdowns and declines in medical research funding not related to the pandemic, interest in psychedelic use to treat addictions and other psychological issues is booming.    The rise in popularity is happening in the business sector and beyond. While specific industries suffered economic blows due to COVID, notable psychedelic companies either went public or secured millions in funding. Currently, the U.S. Food and Drug Administration is conducting clinical trials involving psychedelic substances such as ibogaine, ketamine, and …

Read MorePsychedelic Interest Booms

University of California, Davis researchers have created a non-hallucinogenic version of ibogaine. The new substance could prove just as effective as the psychedelic original used to treat addiction and psychological illnesses such as depression and post-traumatic stress disorder. David Olson, an assistant professor of chemistry at UC Davis, detailed the discovery in the December 2020 issue of Nature.    In the study, a series of rodent experiments showed that mice decreased their alcohol consumption and experienced a delayed opiate relapse …

Read MoreScientists Develop Synthetic Form of Ibogaine